Why We Exist
Our company has noble roots, the culmination of more than a decade of research first started by founder Ronald Lane in an effort to save his wife Sandy Elizabeth Lane from Alzheimer’s. We honor her memory in our SELanetx™ technology name, which also serves as a reminder of our personal empathy for families dealing with neurological disease. Another measure of our dedication – our entire team has worked without salaries during the formative life of our company – preserving a majority of our funds for research.
Today, we are in the later stages of developing the first non-drug, immune-reset platform designed to address neurodegenerative disease at its root cause, starting with ALS. Our proprietary SELanetx™ system represents breakthrough technology -- a device-enabled, outpatient therapy that reprograms immune dysfunction rather than suppressing symptoms.
With compelling preclinical results, globally protected intellectual property, and academic research partners in place, HOPE-Neuron is advancing toward first-in-human trials. This raise allows investors to participate at a critical inflection point as the platform moves from proof-of-concept to clinical execution and commercialization.
Today, we are in the later stages of developing the first non-drug, immune-reset platform designed to address neurodegenerative disease at its root cause, starting with ALS. Our proprietary SELanetx™ system represents breakthrough technology -- a device-enabled, outpatient therapy that reprograms immune dysfunction rather than suppressing symptoms.
With compelling preclinical results, globally protected intellectual property, and academic research partners in place, HOPE-Neuron is advancing toward first-in-human trials. This raise allows investors to participate at a critical inflection point as the platform moves from proof-of-concept to clinical execution and commercialization.